Earnings Data
Report Date
Aug 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.3Last Year’s EPS
0.5Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed picture: clear operational and commercial progress (market share gains, meaningful cost-savings program, completion of a divestiture and reaffirmed guidance) contrasted with material near-term revenue and margin headwinds (notably CORE net sales down ~8.3% YoY, gross/operating margin compression, a $331M goodwill impairment and cash flow pressure). Management emphasized these headwinds are largely transitory and the majority of growth and margin recovery is expected in the second half of 2026, supported by innovation, demand generation and operational improvements.Company Guidance
Market Share Gains — U.S. Store Brand OTC
Significant share improvement in U.S. store brand OTC: company reported a 100 basis point improvement in volume share during the quarter and noted 270 basis points of U.S. store brand OTC volume share gains in Q1; six of seven OTC categories gained share.
Branded Performance and European Wins
Priority branded wins in Europe including ellaOne (+200 bps value share), Jungle Formula (+140 bps), Physiomer (+50 bps), Mederma Cold Sore (+180 bps) and Opill (+40 bps). Compeed showed strong seasonal momentum (Italy +550 bps to 35% share; France +160 bps, approaching 36%).
Operational Enhancement and Cost Savings
Operational enhancement program generated >$7 million of cost savings in Q1 and is on track for approximately $60–$80 million in 2026 with an incremental $20–$40 million expected in 2027.
Strategic Actions — Portfolio Simplification & Capital
Completed Dermacosmetics divestiture (upfront proceeds ~EUR 306 million announced post-quarter), amended $1B revolver extending maturity to 2031, used borrowings to repay $421M Term Loan A, and signaled intent to apply proceeds to debt reduction; returned $40M to shareholders via dividends.
EPS and Guidance Reaffirmation
CORE adjusted EPS of $0.40 and All In adjusted EPS of $0.43; adjusted CORE EPS outperformed expectations. Company reaffirmed full-year 2026 guidance and expects results to be back-half weighted (approx. 30–35% of CORE adjusted EPS in H1; 65–70% in H2).
Innovation and Commercial Model Progress
Advancing 360-degree innovation, store-brand demand-generation and targeted geographic expansion; management expects ~60% of innovation benefits in H2 and highlighted scalable capabilities to grow household penetration (1 point U.S. store brand household penetration ≈ $100M incremental retail sales).
DE:PIG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:PIG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | €9.36 | €10.13 | +8.24% |
Feb 26, 2026 | €11.66 | €10.87 | -6.79% |
Nov 05, 2025 | €16.37 | €14.78 | -9.71% |
Aug 06, 2025 | €21.40 | €18.24 | -14.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Perrigo Company (DE:PIG) report earnings?
Perrigo Company (DE:PIG) is schdueled to report earning on Aug 12, 2026, Before Open (Confirmed).
What is Perrigo Company (DE:PIG) earnings time?
Perrigo Company (DE:PIG) earnings time is at Aug 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Perrigo Company stock?
The P/E ratio of Perrigo Company is N/A.
What is DE:PIG EPS forecast?
DE:PIG EPS forecast for the fiscal quarter 2026 (Q2) is 0.3.
